Skip to content

Lung Cancer Blog

Everything about lung cancer is here.

Menu
  • Home
  • About Us
  • Lung Cancer
    • Lung Cancer News
    • Causes of Lung Cancer
    • Lung Cancer Symptoms
    • Types of Lung Cancer
    • Stages of Lung Cancer
    • Lung Cancer Treatment
    • Lung Cancer Drugs
    • Lung Cancer In Ayurveda
    • Chinese Herbs For Lung Cancer
  • Researches
  • Studies
  • Stories
  • Sitemap
  • Contact Us
Menu
Non-Small-Cell Lung Cancer (NSCLC)

FDA Approves FoundationOne CDx in Non-Small Cell Lung Cancer

Posted on March 21, 2022
Post Views: 314

Non-Small-Cell Lung Cancer (NSCLC)U.S. Food and Drug Administration (FDA) has approved the FoundationOne CDx as a companion diagnostic to guide treatment selection for patients with non-small cell lung cancer. This approval applies to the use of FoundationOne CDx (Foundation Medicine) to identify NSCLC patients whose tumors have EGFR exon 19 deletions or exon 21 L858R alterations and are appropriate for treatment with FDA-approved EGFR tyrosine kinase inhibitors. This CDx is an in vitro diagnostic device and it is designed to detect substitutions, insertion and deletion alterations. The FDA approval works as a companion diagnostic to guide treatment selection for certain non-small cell lung cancer patients.

This approval is the first FDA-approved tissue-based broad companion diagnostic and the test results help to inform immunotherapy decisions. EGFR mutations are the second most common oncogenic drivers in NSCLC. FoundationOne CDx offers oncologists the flexibility in selection of the right therapy for the patients and also ensures that all FDA approved treatment options are being considered. FoundationOne CDx is the next-generation sequencing based in vitro diagnostic device and helps in detection of substitutions, insertion and deletion alerations and genomic signatures as well.

Mia Levy, Chief Medical Officer at Foundation Medicine, said, “Cancer treatment decision-making is growing more complex as we learn more about the mutations that drive cancers to grow and new treatments become available to target those changes.” “We believe securing a third group companion diagnostic approval for FoundationOne CDx is another critical step toward simplifying the decision-making process for oncologists and their patients by allowing them to uncover all FDA approved treatment options for this indication through one test,” he added.

The information shared in this blog is for educational purposes only. You should consult your medical practitioner for any healthcare issues.

Subscribe to our newsletter or follow us on Twitter or Facebook today and never miss an update!

  • Click to share on Facebook (Opens in new window) Facebook
  • Click to share on X (Opens in new window) X
  • Click to share on Pinterest (Opens in new window) Pinterest
  • Click to share on Threads (Opens in new window) Threads
  • Click to share on WhatsApp (Opens in new window) WhatsApp
  • Click to share on Reddit (Opens in new window) Reddit
  • Click to share on Tumblr (Opens in new window) Tumblr
  • Click to share on Pocket (Opens in new window) Pocket
  • Click to share on Telegram (Opens in new window) Telegram

Like this:

Like Loading...

Subscribe Us

Popular Articles

  • Lung Cancer Treatment in Ayurveda (7,325)
  • Lung Cancer: Symptoms and Treatment (5,657)
  • What is Non-Small-Cell Lung Cancer? (5,552)

Recent Comments

  • Lung Cancer on New Study To Help Advance Research In Lung Cancer
  • Laurie B Grimes on New Study To Help Advance Research In Lung Cancer
  • Lung Cancer on Asbestos and Lung Cancer – What’s The Link?

Recent Articles

  • Study: Wildfire Smoke Exposure Affects Lung Cancer Survival June 2, 2025
  • Predicting Lung Cancer Risk with AI based Deep Learning Model May 26, 2025
  • FDA Grants Accelerated Approval to Telisotuzumab Vedotin-tllv for NSCLC May 19, 2025
  • Heart-Sparing Technique in Lung Cancer Radiotherapy May 12, 2025
  • Origins of Common Lung Cancer Linked to Smoking Discovered May 5, 2025

Lung Cancer Blog

Lung Cancer Blog provides all lung cancer related information for educational purposes.

Disclaimer

Some post may contain affiliate links, purchasing that product not going to cost extra but by your purchase Lung Cancer will get some little commission and that amount will help in surviving this website. So, please don’t hesitate to buy from these affiliate links.

Contact Us

If you have any query or suggestions about our blog, please feel free to email us at  lungcancersymptomsx@gmail.com.

Copyright © 2012 - 2025 Lung Cancer Blog. Wordpress by Vipasha.
  • Privacy Policy
  • About Us
  • Sitemap
  • Contact Us
%d